Skip to content

Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study

Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02528149
Enrollment
34
Registered
2015-08-19
Start date
2013-09-30
Completion date
2014-12-31
Last updated
2015-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromuscular Dysplasia, Renal Artery Stenosis

Keywords

Fibromuscular Dysplasia, dysplastic renal artery aneurysm, renal artery aneurysms, non atheromatous, dysplastic, anatomopathologic, genetic

Brief summary

Fibromuscular dysplasia (FMD) is localized structural defects in the arterial wall, whose innate or acquired character is still unknown. This segmental non atheromatous injury, leads to stenosis of the arteries of small and medium caliber. Renal arteries are the most commonly affected with 60-75% of total fibrodysplasia. Three histological subtypes have been described: intimal, medial and peri-medial. They are not mutually exclusive and can be observed in the same patient. This is a rare blood disease, occurring in children and young adults. In this young population with long life expectancy, these aneurysmal lesion are associated with 10% risk of rupture. To date, no data have shown in the literature that FMD is link to genetic causes, or if there is specific histopathologic lesions for non-atherosclerotic renal artery aneurysms. To answer these questions, Cardiovascular Surgery Unit of the University Hospital of Saint-Etienne, French national reference center for renal artery surgery, in association with the Reference Center for Rare Vascular Disease in Paris, designed the first study for pathological and genetic characteristics of dysplastic renal artery aneurysms in young patients.

Interventions

PROCEDUREtissue of adjacent part and aneurysm of renal aneurysm

the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis

OTHERblood sample

Sponsors

Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with one or more Renal artery aneurysm (RAA), not eligible for endovascular treatment, have been operated at the Hospital of Saint-Etienne, with tissue (adjacent part and aneurysm) cryopreserved in liquid nitrogen in renal lab and then sent in genetic lab in Georges Pompidou European Hospital (EHGP ). * Patient (or parent/person having parental authority) Affiliate or entitled to a social security scheme. * Signature of patient consent (or parents or holder of parental authority)

Exclusion criteria

* Patient not included in the tissue collection in Georges Pompidou European Hospital (EHGP ). * Patient refusing to participate in the study and / or genetic analysis or, for juvenile patients, parents or holder of parental authority refusing the minor patient to be involved in the study and / or genetic analysis. * Patient with FMD whose samples in the tissue collection did not concern aneurysm.

Design outcomes

Primary

MeasureTime frameDescription
anatomopathological characteristics of renal aneurysmsday 1Anatomopathological criteria is a composite outcome : Presence of a media thickness, the media disappearance zones, loss of smooth muscle cells (SMC) in the media with replacement by fibrosis, disorganization of SMC, aneurysms, dissections, discontinuity of the internal elastic lamina, and intimal thickening due to myointimal hyperplasia, abnormalities of proteins of the extracellular matrix.

Secondary

MeasureTime frameDescription
genetic markers in blood samplesday 1identify specific genetic markers (mutation, variant) to characterize genes involved in fibromuscular dysplasia
genetic markers in aneurysm tissueday 1identify specific genetic markers (mutation, variant) to characterize genes involved in fibromuscular dysplasia

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026